ArticleFrontiers in oncology2026
Radiomic analysis of the peritumoral zone identifies imaging signatures of glioma invasion associated with HSP70 expression.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Glioma invasion into surrounding brain tissue drives disease progression but is challenging to evaluate with conventional MRI. This study aimed to determine whether radiomic features extracted from the peritumoral zone capture biologically relevant invasion-associated imaging phenotypes, using membrane-bound Hsp70 (mHsp70) as a molecular correlate. Methods: A retrospective study was performed using preoperative MRI data from 80 patients with glioma, including adult glioblastoma (GBM), adult lower-grade glioma (LGG), and pediatric GBM/ATRT cases. Voxel-wise radiomic features were extracted from the peritumoral region and used to train a stochastic gradient descent (SGD) classifier to distinguish GBM-associated invasion-enriched imaging phenotypes from LGG-associated comparison phenotypes. Patient-level cohort separation was used throughout model development to prevent data leakage. Feature importance was assessed using SHAP analysis. In a biologically validated subgroup of 23 patients, membrane-bound Hsp70 (mHSP70) expression was quantified in peritumoral tissue samples using confocal microscopy. Patient-level radiomic invasion metrics were correlated with mHsp70 fluorescence intensity. Results: The SVM classifier demonstrated good discriminative performance, achieving an AUC of 0.875 (95% CI: 0.736-0.896) in the independent test cohort. SHAP analysis identified higher-order texture features, including GLCM-, GLRLM-, and LoG-derived radiomic descriptors, as major contributors to model predictions. Reproducibility analysis demonstrated good-to-excellent agreement for all 20 SHAP-selected features, with mean ICC values ranging from 0.859 to 0.986. In the biological validation subgroup, the radiomics-derived Invasion Burden Index (IBI) showed a significant positive correlation with mHsp70 expression (Spearman ρ = 0.67, p = 0.0004, 95% CI: 0.232-0.805, n = 23). Leave-one-out sensitivity analysis demonstrated stable correlations, indicating that the observed association was not driven by individual cases. Regions exhibiting elevated invasion-associated radiomic signatures frequently extended beyond the conventional MRI-defined tumor margin and showed spatial correspondence with areas of subsequent tumor progression on follow-up imaging. Conclusions: Voxel-wise radiomic analysis of the peritumoral zone identifies invasion-associated imaging phenotypes that correlate with membrane Hsp70 expression, a biological marker associated with aggressive tumor behavior. These findings support the potential utility of radiomic invasion mapping as a non-invasive tool for characterizing infiltrative glioma biology and generating hypotheses regarding patterns of tumor progression. Further prospective studies with spatially matched biological validation are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.